Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Share-based Compensation (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of Share-based Compensation data on record, last reported at $13.4 million in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 168.58% year-over-year to $13.4 million; the TTM value through Dec 2025 reached $36.7 million, changed N/A, while the annual FY2025 figure was $70.0 million, 275.51% up from the prior year.
  • Share-based Compensation reached $13.4 million in Q4 2025 per CAI's latest filing, down from $13.7 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $13.7 million in Q3 2025 and bottomed at $4.7 million in Q3 2024.